A novel cancer vaccine that stimulates T-cell activity in KRAS -driven pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) has shown promise in early testing.

The investigational vaccine, ELI-002, developed by Elicio Therapeutics, is designed to train the immune system to recognize and attack tumor cells harboring mutant KRAS, which is present in roughly 93% of PDAC and 50% of CRC.

While only in phase 1 testing, the vaccine elicited strong T-cell responses in more than 80% of patients with minimal residual mutant KRAS disease following standard locoregional treatment. This strong response correlated with longer recurrence-free and overall survival, the investigators, led by Zev Wainberg, MD, with University of California, Los Angeles, reported online earlier this

See Full Page